This episode of TWiV is focused on COVID-19 vaccines and antibodies: who should get boosters, whether a variant matched mRNA vaccine is superior to a historical vaccine, and how the interval between vaccination and infection influences the quality of the antibody response.
Intranasal administration with a single dose of a chimpanzee adenovirus-vectored SARS-CoV-2 vaccine induces potent immune responses.
TWiV reviews an experimental, intranasally administered SARS-CoV-2 vaccine that utilizes adenovirus vectors to deliver three viral proteins and induces immunity to ancestral and variant isolates. Hosts: Vincent Racaniello, Alan Dove, Rich Condit, and Kathy Spindler Click arrow to playDownload TWiV 867 (128 MB .mp3, 107 min)Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Show notes at microbe.tv/twiv
A heterologous vaccine regimen consisting of a first dose of the AstraZeneca vaccine and a second dose of the Pfizer vaccine induces a stronger immune response than a regimen consisting of two doses of the AstraZeneca vaccine.
Daniel Griffin provides a clinical report on COVID-19, and Shane Crotty explains a study of antibodies, B cells and T cells in patients which suggests that immunological memory to SARS-CoV-2 might be long-lived. Click arrow to playDownload TWiV 684 (110 MB .mp3, 184 min)Subscribe (free): iTunes, Google Podcasts, RSS, email Show notes at microbe.tv/twiv
Some have suggested that pre-existing cross-reactive memory T cells in people with no prior exposure to SARS-CoV-2 may have a protective effect. However, recent findings indicate that this may not be the case.